Trial Profile
A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND 100947, NSC 742460]) in Combination With Intensive Multi-Agent Interval Compressed Therapy for Patients With High-Risk Rhabdomyosarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Cixutumumab (Primary) ; Temozolomide (Primary) ; Cyclophosphamide; Dactinomycin; Doxorubicin; Etoposide; Ifosfamide; Irinotecan; Vincristine
- Indications Rhabdomyosarcoma
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2018 Results evaluating the feasibility and efficacy of adding cixutumumab or temozolomide to the ARST0431 intensive chemotherapy backbone published in the Cancer
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.